8 European countries, 48 centres
Stent implantation
Double-blind
randomisation
n = 1005
Clopidogrel 300mg od Aspirin 325mg od
Clopidogrel 75mg od Aspirin 325mg od
Ticlopidine 250mg bid Aspirin 325mg od
Clopidogrel 75mg od Aspirin 325mg od
Clopidogrel 75mg od Aspirin 325mg od
D1
D2 to D28
The CLASSICS trial: study design
Ticlopidine 250mg bid Aspirin 325mg od
The CLASSICS trial Primary assessment: safety
Principal criteria
Major peripheral or bleeding complications
Neutropaenia
Thrombocytopaenia
EPD for non-cardiac adverse events
Secondary criteria
Occurrence of adverse events grouped by category
Values and change from baseline of laboratory parameters
The CLASSICS trial Secondary assessment: efficacy
Global mortality
Incidence of major cardiac events
Cardiovascular death
Myocardial infarction
Target lesion revascularisation
Prevention of subacute thrombosis after coronary stenting
Double-blind, comparison between two regimens 2000 patients, 100 centres in the USA
PTCA
1 MONTH
1 YEAR
Placebo + aspirin
Clopidogrel 75 mg + aspirin
Placebo + aspirin
Clopidogrel 75 mg + aspirin
6-24 h before PTCA
The CREDO trial: study design
Clopidogrel 300 mg loading dose + aspirin
Clopidogrel for coronary stenting: current status
Use of stenting in coronary angioplasty is increasing
Complementary antithrombotic and antiplatelet therapies are becoming established to reduce the risk of subacute thrombosis after coronary stenting
Ticlopidine + aspirin have proven antiplatelet efficacy in coronary stenting
The CLASSICS trial compares the safety of ticlopidine + aspirin with clopidogrel (with and without a loading dose) + aspirin for coronary stenting
The CREDO trial is underway to assess the efficacy of clopidogrel + aspirin at 30 days and 1 year following PTCA, with or without stenting